Vebreltinib

伯瑞替尼

Report date: 2026/04/20 20:01:59
NME

Base Information

Drug NameVebreltinib
Drug Alias NameBozitinib万比锐PLB-1001CBT-101APL-101 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHepatocyte growth factor receptor inhibitors
TargetsHepatocyte growth factor receptorReceptor-type tyrosine-protein phosphatase zeta
Therapy Area/IndicationsGastroesophageal Junction NeoplasmsSolid tumoursHepatic Insufficiency +[19] 
Global Approved IndicationsCarcinoma, Non-Small-Cell Lung
Approved Indications in ChinaCarcinoma, Non-Small-Cell Lung
Original Approved Country/TerritoryMainland China
Original Approved Date2023/11/16
Country/TerritoryCanadaUnited StatesSingapore +[13] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesCrown Bioscience(Taicang)Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesAsymchem Life Science (Tianjin) Co LtdStrata OncologyApollomics Inc +[7] 
Inactive CompaniesFudan University
Active IndicationsGastroesophageal Junction NeoplasmsSolid tumoursHepatic Insufficiency +[15] 
Inactive IndicationsCarcinoma, Renal CellCarcinoma, HepatocellularGlioma +[4] 

Other Information

ATC CodeN/A
Related LinksDrugBankKEGG